Upper Limb Strength and Function Changes during a One-Year Follow-Up in Non-Ambulant Patients with Duchenne Muscular Dystrophy: An Observational Multicenter Trial

Introduction Upper limb evaluation of patients with Duchenne Muscular Dystrophy is crucially important to evaluations of efficacy of new treatments in non-ambulant patients. In patients who have lost ambulation, there are few validated and informative outcome measures. In addition, longitudinal data demonstrating sensitivity to clinical evolution of outcome measures over short-term periods are lacking. Patients and Methods We report here the results of a one-year multicenter study using specifically designed tools to assess grip, pinch strength, and hand function in wheelchair-bound patients. Our study assessed 53 non-ambulant patients with Duchenne muscular dystrophy aged 17.1 ± 4.8 years (range: 9 – 28.1 years). The average Brooke functional score of these patients was 4.6 ± 1.1. The average forced vital capacity was 44.5% predicted and 19 patients used non-invasive ventilation. Patients were assessed at baseline, 6 months, and one year using the Motor Function Measure and innovative devices (namely the MyoSet composed of MyoGrip, MyoPinch, and MoviPlate). Results Our study confirmed preliminary data previously reported regarding feasibility of use and of reliability of the MyoSet and the correlation at baseline between distal strength and clinical outcomes such as FVC, Brooke score, age, and duration since loss of ambulation. A significant correlation was observed between the distal upper limb strength and clinical variables. The sensitive dynamometers (MyoGrip and MyoPinch) and MoviPlate captured a 12-month change in non-ambulant Duchenne muscular dystrophy patients of all ages. Trial Registration ClinicalTrials.gov NCT00993161 NCT00993161

[1]  B. Darras Spinal muscular atrophies. , 2015, Pediatric clinics of North America.

[2]  E. Bertini,et al.  Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy , 2014, Neuromuscular Disorders.

[3]  G. Comi,et al.  6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes , 2014, PloS one.

[4]  Elizabeth Vroom,et al.  Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy , 2013, Developmental medicine and child neurology.

[5]  J. Mendell,et al.  Eteplirsen for the treatment of Duchenne muscular dystrophy , 2013, Annals of neurology.

[6]  R. Bajcsy,et al.  P.2.4 Upper extremity reachable workspace evaluation in DMD using Kinect , 2013, Neuromuscular Disorders.

[7]  Jay J. Han,et al.  The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measur , 2013, Muscle & nerve.

[8]  S. Peltz,et al.  THE 6-MINUTE WALK TEST AND OTHER ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: LONGITUDINAL NATURAL HISTORY OBSERVATIONS OVER 48 WEEKS FROM A MULTICENTER STUDY , 2013, Muscle & nerve.

[9]  E. Bertini,et al.  Early neurodevelopmental assessment in Duchenne muscular dystrophy , 2013, Neuromuscular Disorders.

[10]  Eugenio Mercuri,et al.  Muscular dystrophies , 2013, The Lancet.

[11]  Lise Worthen-Chaudhari,et al.  Proof of Concept of the Ability of the Kinect to Quantify Upper Extremity Function in Dystrophinopathy , 2013, PLoS currents.

[12]  T. Voit,et al.  Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients , 2013, Neuromuscular Disorders.

[13]  R. Écochard,et al.  Responsiveness of the motor function measure in neuromuscular diseases. , 2012, Archives of physical medicine and rehabilitation.

[14]  E. Mazzone,et al.  International workshop on assessment of upper limb function in Duchenne Muscular Dystrophy , 2012, Neuromuscular Disorders.

[15]  E. Mazzone,et al.  A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy , 2012, Developmental medicine and child neurology.

[16]  Ruzena Bajcsy,et al.  Development and Application of Stereo Camera-Based Upper Extremity Workspace Evaluation in Patients with Neuromuscular Diseases , 2012, PloS one.

[17]  J. Pépin,et al.  Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[18]  N. Bresolin,et al.  Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures , 2011, BMC Neurology.

[19]  H. Stam,et al.  Upper limb function in adults with Duchenne muscular dystrophy. , 2011, Journal of rehabilitation medicine.

[20]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[21]  Munish C. Gupta,et al.  The Natural History of Cardiac and Pulmonary Function Decline in Patients With Duchenne Muscular Dystrophy , 2011, Spine.

[22]  R. Finkel,et al.  Assessing upper limb function in nonambulant SMA patients: Development of a new module , 2011, Neuromuscular Disorders.

[23]  B. Ceulemans,et al.  Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: Results from a 12 month, double-blind, randomized placebo-controlled trial , 2011, Neuromuscular Disorders.

[24]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[25]  K. Gordon,et al.  Impact of steroids on surgical experiences of patients with duchenne muscular dystrophy. , 2010, Pediatric neurology.

[26]  Jay J. Han,et al.  The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy , 2010, Muscle & nerve.

[27]  Craig McDonald,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care , 2010, The Lancet Neurology.

[28]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[29]  F. Rivier,et al.  Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. , 2009, Human molecular genetics.

[30]  F. Leturcq,et al.  Clinical Heterogeneity of Duchenne Muscular Dystrophy (DMD): Definition of Sub-Phenotypes and Predictive Criteria by Long-Term Follow-Up , 2009, PloS one.

[31]  Fabiana Luisa Mattar,et al.  Hand weakness in Duchenne muscular dystrophy and its relation to physical disability , 2008, Neuromuscular Disorders.

[32]  S. Chow,et al.  Sample Size Calculations In Clinical Research , 2007 .

[33]  G. Yavuzer,et al.  Clinimetric properties of the Duruoz hand index in patients with stroke. , 2007, Archives of physical medicine and rehabilitation.

[34]  R. McCarter,et al.  Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy , 2007, Muscle & nerve.

[35]  M. Main,et al.  The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. , 2001, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[36]  A L Hull,et al.  Assessment of hand function in Duchenne muscular dystrophy. , 1993, Archives of physical medicine and rehabilitation.

[37]  W. Stuberg,et al.  Reliability of quantitative muscle testing in healthy children and in children with Duchenne muscular dystrophy using a hand-held dynamometer. , 1988, Physical therapy.

[38]  V. Dubowitz,et al.  Quantitation of muscle function in children: A prospective study in duchenne muscular dystrophy , 1982, Muscle & nerve.

[39]  J. Fermanian,et al.  [A motor function measurement scale for neuromuscular diseases - description and validation study]. , 2006, Revue neurologique.

[40]  Jacques Fermanian,et al.  A motor function measure for neuromuscular diseases. Construction and validation study. , 2005, Neuromuscular disorders : NMD.

[41]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.